A pivotal Phase 3 trial (inMIND) has demonstrated the efficacy of tafasitamab in combination with lenalidomide and rituximab for treating relapsed or refractory follicular lymphoma (FL). The primary endpoint of progression-free survival (PFS) was met, as were crucial secondary endpoints.
Tafasitamab, a monoclonal antibody targeting CD19, displayed no new safety concerns when added to the standard care.
FL, the most common indolent B-cell non-Hodgkin lymphoma, affects a significant number of patients with limited treatment options for relapsed or refractory cases.
Based on the positive results, Incyte anticipates filing a supplemental license application for tafasitamab in FL by the end of the year.
This breakthrough offers hope for FL patients whose disease has progressed after initial treatment.
Previously approved by the FDA and EMA for diffuse large B-cell lymphoma (DLBCL), tafasitamab has demonstrated efficacy in FL.
It is marketed as Monjuvi® and Minjuvi® in the United States, Europe, and Canada.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
